Last updated: 11/03/2018 16:45:31

Coreg and HSRs-Updated Analysis

GSK study ID
114522
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic reaction/angioedema-Updated Analysis
Trial description: A cluster of reports of hypersensitivity reactions among patients who switched from carvedilol (immediate release formulation, referred to hereafter as carvedilol) to carvedilol extended release was received during the initial post-launch period of carvedilol extended release. In follow up to this observation, product labeling for both agents was updated and a nested case control study was subsequently conducted to examine the risk of serious hypersensitivity reactions i.e. anaphylactic reaction and/or angioedema among patients who used carvedilol extended release compared to carvedilol and separately compared to other long acting beta(β)-blockers. This proposed analysis is an update to the previously conducted analysis using the same database, LabRx, now containing 2 additional years of data, which should provide a larger number of carvedilol extended release exposed subjects.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Hypersensitivity reactions (anaphylactic reaction/ angioedema)

Timeframe: Hypersensitivity reactions among users in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009

Secondary outcomes:
Not applicable
Interventions:
  • Drug: Carvedilol immediate release only
  • Drug: Carvedilol extended release only
  • Drug: Long acting β-blockers
  • Drug: Other α1/β-adrenergic antagonists
  • Drug: Short acting Non-selective β-blockers and short acting β1-Selective agents
  • Other: No β-blocker
  • Enrollment:
    1
    Primary completion date:
    Not applicable
    Observational study model:
    Case-Control
    Time perspective:
    Retrospective
    Clinical publications:
    Koro C, Sowell M, Stender M. An assessment of the association between carvedilol exposure and severe hypersensitivity reactions, angioedema, and anaphylactic reactions: a retrospective nested case-control analysis. . [Clin Ther]. 2012;34(4):870-77.
    Koro C, Sowell M, Stender M. An assessment of the association between carvedilol exposure and severe hypersensitivity reactions, angioedema, and anaphylactic reactions: a retrospective nested case-control analysis. Clin Ther. 2012;34(4):870-77.
    Medical condition
    Hypersensitivity
    Product
    carvedilol, propranolol
    Collaborators
    Not applicable
    Study date(s)
    June 2010 to March 2011
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    Not applicable
    Accepts healthy volunteers
    No
    • At least one prescription claim for a β-blocker during follow-up time available in the database.
    • At least one month of enrollment in the healthcare plan
    • None

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Clinical study report
    Available language(s): English
    Scientific result summary
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2011-15-03

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website